CCL14 testing to guide clinical practice in patients with AKI: Results from an international expert panel

Urinary C-C motif chemokine ligand 14 (CCL14) is a strong predictor of persistent stage 3 acute kidney injury (AKI). Multiple clinical actions are recommended for AKI but how these are applied in individual patients and how the CCL14 test results may impact their application is unknown. We assembled an international panel of 12 experts and conducted a modified Delphi process to evaluate patients at risk for persistent stage 3 AKI (lasting 72 hours or longer). Using a Likert scale, we rated 11 clinical actions based on international guidelines applied to each case before and after CCL14 testing and analyzed the association between the strength and direction of recommendations and CCL14 results. The strength and direction of clinical recommendations were strongly influenced by CCL14 results (P < 0.001 for the interaction). Nine (82%) recommendations for clinical actions were significantly impacted by CCL14 results (P < 0.001 comparing low to highest CCL14 risk category). Most recommendations for care of patients with stage 2-3 by an international panel of experts were strongly modified by CCL14 test results. This work should set the stage for clinical practice protocols and studies to determine the effects of recommended actions informed by CCL14. •Urinary C-C motif chemokine ligand 14 (CCL14) is a newly discovered biomarker for persistent AKI.•We sought to determine how CCL14 test results might change clinical recommendations for AKI.•Twelve experts conducted a modified Delphi process to evaluate patients at risk for persistent AKI.•Nine (82%) recommendations for clinical actions were significantly impacted by CCL14 results.